MGMT and glioblastoma: Methylation levels ≥8% of the CpGs targeted in the MGMT promoter as well as methylation levels <55% of the mean of CpGs 01–03, mean of CpGs 09–13, and methylation levels of CpG 03, CpG 07, and CpG 13 offer survival benefit for GBM patients.